News | Artificial Intelligence | November 07, 2019

Mirada Medical Announces New Wave of Global Installations of DLCExpert

Announcement builds on Mirada Medical’s FDA clearance of DLCExpert in 2018, giving the deep learning autocontouring system one year of clinically approved experience

Bladder Abdomen Pelvis image with DLCExpert

November 7, 2019 — Mirada Medical, a global leader in artificial intelligence (AI) software for the treatment of cancer, announced further global installations of DLCExpert, the world’s first commercially available AI-powered autocontouring software for cancer treatment planning and the only system with over one year of clinically proven use.

Mirada’s advanced software products targeting cancer care are in daily clinical use at over 1,400 hospitals worldwide and its breakthrough DLCExpert AI system has been recently deployed at multiple global centers of clinical excellence including Moffitt Cancer Center, Mayo Clinic, UMC Groningen, and The Christie NHS Foundation Trust.

The company has today announced further installations at leading cancer centers in the United States and Europe including Northwestern Hospital (IL), City of Hope (CA), CHU Liège, and Royal Surrey NHS Foundation Trust.

Amato J. Giaccia, M.D., director of the Institute of Radiation Oncology at Oxford University and  Chairperson of the Mirada Medical Strategic Advisory Board, said: “With Mirada Medical’s  deployments of DLCExpert now benefiting cancer patients globally and on a daily basis , I couldn’t be more excited to be a part of this exciting company as Chairman of the Strategic Medical Advisory Board.”

Giaccia continued, “I believe that automated contouring of organs at risk (OARs) using AI is revolutionizing the radiotherapy planning process. Not only can AI free up doctors’ time, which is a huge benefit for patients, but it may also enable better outcomes.

“This is not just about producing faster workflows, it’s also about the overall quality of treatment plans, as AI will be able to help identify normal tissue and preserve at risk tissue. This, in turn, will help deliver greater personalised care, while potentially contributing to improved outcomes.”

These milestone achievements track alongside a continually growing body of clinical evidence, produced in partnership with global academic medical partners, that underlines the real-word benefit obtained by clinics who have deployed the world-first deep learning autocontouring system, Mirada’s DLCExpert. In particular, multiple published clinical studies provide robust evidence which confirms that software generated contours, reviewed and refined by clinicians, represent a viable strategy for reducing contouring time while also reinforcing compliance with established clinical standards. Research published by the American Association of Physicists in medicine has indicated time savings of up to 77 percent for some organs, resulting from editing software generated contours compared to the standard clinical workflow.

Charlotte Brouwer, medical physicist at the Department of Radiation Oncology, University Medical Center Groningen, said: “The collaboration between UMC Groningen and Mirada Medical has produced autocontouring models that encode according to consensus guidelines, established by an international panel of experts for organs at risk. These DLCExpert models are now deployed in our routine clinical workflows, forming a key part of our treatment planning for all patients with cancers in the head and neck or prostate regions.

“Thanks to DLCExpert, we now enjoy measurable and consistent time-savings, which we expect to translate to other institutions," she continued. "Perhaps the clearest indications of their clinical acceptance were the loud objections of our RT planning team when the models were briefly unavailable during routine maintenance!”

Mirada Medical CEO Hugh Bettesworth said: “I am delighted that Mirada’s technology is being deployed so widely and that patients are benefitting from it every day. We hear a lot of talk about bringing artificial intelligence to medicine - I am immensely proud that it is Mirada’s brilliant team of scientists and engineers who have worked with our customers, our clinical advisors, and the regulators in the USA and Europe, and have delivered every-patient clinical advances for cancer treatment planning using artificial intelligence.”

For more information: www.axicom.com

Related content:

VIDEO: Artificial Intelligence Automatic Contouring and Segmentation For Radiotherapy

Mirada Medical Showcases DLCExpert AI-Based Radiotherapy Contouring Software at ASTRO 2018

Related Content

Altamont’s zero-footprint solution, CaptureWare, allows Mach7’s Enterprise Imaging Platform (EIP) to ingest more DICOM and/or non-DICOM data from various sources in a facility
News | PACS | February 20, 2020
February 20, 2020 — Mach7 announced its partnership with Altamont
Chest CT imaging of patient. #coronavirus #nCoV2019 #2019nCoV #COVID19

Examples of typical chest CT findings compatible with COVID-19 pneumonia in patients with epidemiological and clinical presentation suspicious for COVID-19 infection. This image is part of the original research, Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR, published Feb. 19, 2020, in Radiology Online.

News | Computed Tomography (CT) | February 19, 2020
February 19, 2020 — In new research
Sponsored Content | Videos | Enterprise Imaging | February 19, 2020
Bill Lacy, vice president, Medical Informatics at FUJIFILM Medic...
Sponsored Content | Videos | Flat Panel Displays | February 19, 2020
EIZO medical monitors were showcased recently at RSN...
Recognized as the “Pulitzer Prize of the business press,” the Jesse H. Neal Award finalists are selected for exhibiting journalistic enterprise, service to the industry and editorial craftsmanship
News | Radiology Business | February 19, 2020
February 19, 2020 — Connectiv, a division of The Software and Information Industry Association (SIIA), has announced
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
The Caption Guidance software uses artificial intelligence to guide users to get optimal cardiac ultrasound images in a point of care ultrasound (POCUS) setting.

The Caption Guidance software uses artificial intelligence to guide users to get optimal cardiac ultrasound images in a point of care ultrasound (POCUS) setting.

News | Artificial Intelligence | February 13, 2020
February 13, 2020 — The U.S.
The Candelis ImageGrid Plus PACS Server is an ultra-high-performance platform that can support high volume healthcare environments of 1,000 plus modalities
News | PACS | February 12, 2020
February 12, 2020 — The Candelis ImageGrid Plus...